Sampling Human, a San Diego, CA-based early stage, life science technology company that has developed a diagnostic platform that harnesses genetically engineered cells to analyze other cells in their environment, raised $2m in funding.
The round was led by i&i Biotech Fund (i&i Bio) with participation from Longevitytech.fund and Formic Ventures.
The company intends to use the funds to further advance R&D, hiring, and business development.
Led by Daniel Georgiev, co-founder and CEO, Sampling Human is a synthetic biology diagnostics company developing novel methods for the early detection of disease. The company has developed diagnostic reagent kits for the liquid biopsy of healthy and diseased cells and a proprietary method of harnessing living cells to analyze other cells. Sampling Human engineers and manufactures accessible tools that elevate sensitivity and increase speed of assay well beyond performance limits of complex instruments such as flow cytometry. Its novel platform, “Diagnostics On Target” (DOT), is a cell diagnostics technology that translates vast amounts of single cell data into clinical practice to improve early disease detection and treatment monitoring.
FinSMEs
18/04/2022